Plain-English translation of NCT07525375 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Asthma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether glycopyrronium, a new medication that can be inhaled, helps children with asthma breathe better when added to their regular asthma controller inhalers. The trial will compare two different doses of this medication against a placebo (a dummy inhaler with no active medicine) to see which dose works best and is safest. All children will continue taking their regular asthma medications throughout the study.
Many children with asthma still have symptoms even when taking standard controller medications. This trial is exploring whether adding this medication to current treatment can improve lung function and give children better asthma control.
You likely qualify if…
You likely don't qualify if…
You will come to the clinic for a 3-week run-in period first, where you'll use only your regular asthma inhaler to establish a baseline. Then you'll enter three separate 3-week treatment periods where you'll randomly receive one of three options: the new medication at a higher dose, the new medication at a lower dose, or a placebo inhaler—all added to your regular inhaler. The order you receive each treatment will be randomized. After all treatments are finished, you'll have one final follow-up visit about 2 weeks later to check that everything is safe.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
United States